{rfName}
Ri

Indexed in

Documents and files

rifabutin_gisbert_Pathogens_2021.pdf 5217.65 Mb

License and use

Icono OpenAccess

Citations

109

Altmetrics

Analysis of institutional authors

Gisbert, JpCorresponding Author

Share

February 15, 2021
Publications
>
Review
Sí

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review

Publicated to:Pathogens. 10 (1): 1-29 - 2021-01-01 10(1), DOI: 10.3390/pathogens10010015

Authors: Gisbert, JP

Affiliations

‎ Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28006, Spain - Author
‎ Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS IP, Gastroenterol Unit, Madrid 28006, Spain - Author

Abstract

Nowadays, apart from having to know first-line Helicobacter pylori eradication regimens well, we must also be prepared to face treatment failures. The aim of this review is to summarize the role of rifabutin in the management of H. pylori infection. Bibliographical searches were performed in PubMed. Data on resistance and efficacy of rifabutin-containing regimens on H. pylori eradication were meta-analyzed. Mean H. pylori rifabutin resistance rate (39 studies, including 9721 patients) was 0.13%; when studies only including patients naive to H. pylori eradication treatment were considered, this figure was even lower (0.07%). Mean H. pylori eradication rate (by intention-to-treat) with rifabutin-containing regimens (3052 patients) was 73%. Respective cure rates for second-, third-, fourth- and fifth-line therapies, were 79%, 69%, 69% and 72%. Most studies administered rifabutin 300 mg/day, which seemed to be more effective than 150 mg/day. The ideal length of treatment remains unclear, but 10-12-day regimens are generally recommended. Adverse events to rifabutin treatment in H. pylori studies were relatively infrequent (15%), and severe adverse events were exceptional (myelotoxicity was the most significant, although always reversible). In summary, rifabutin-containing therapy represents an encouraging strategy generally restricted, at present, to patients where previous (usually multiple) eradication regimens have failed.

Keywords

h. pylorihelicobacter pylorirescuerifabutinHH. pyloriHelicobacter pyloriPyloriRescueRifabutinTreatment

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Pathogens due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 58/137, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Microbiology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Immunology and Microbiology (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 3.28. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 4.3 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 18.67 (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-02, the following number of citations:

  • WoS: 32
  • Scopus: 52
  • Europe PMC: 19

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 70.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 70 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 239.7.
  • The number of mentions on the social network X (formerly Twitter): 20 (Altmetric).
  • The number of mentions in news outlets: 30 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: http://hdl.handle.net/10486/697620

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (PEREZ GISBERT, FRANCISCO JAVIER) and Last Author (PEREZ GISBERT, FRANCISCO JAVIER).

the author responsible for correspondence tasks has been PEREZ GISBERT, FRANCISCO JAVIER.